YAKUGAKU ZASSHI
The Pharmaceutical Society of Japan, established in 1880, is one of Japan’s oldest and most distinguished academic societies. The Society currently has around 15,000 members. It publishes three monthly scientific journals. Chemical and Pharmaceutical Bulletin (Chem. Pharm. Bull.) began publication in 1953 as Pharmaceutical Bulletin. It covers chemistry fields in the pharmaceutical and health sciences. Biological and Pharmaceutical Bulletin (Biol. Pharm. Bull.) began publication in 1978 as the Journal of Pharmacobio-Dynamics, which then merged the Journal of Health Science, another former Society’s journal, in 2012. It covers various biological topics in the pharmaceutical and health sciences. Yakugaku Zasshi (Japanese for “Pharmaceutical Science Journal”) has the longest history, with publication beginning in 1881. Yakugaku Zasshi is published mostly in Japanese, except for some articles related to clinical pharmacy and pharmaceutical education, which are published in English. The main aim of the Society’s journals is to advance the pharmaceutical sciences with research reports, scientific communication, and high-quality discussion. The average review time for articles submitted to the journals is around one month for first decision. The complete texts of all of the Society’s journals can be freely accessed through J-STAGE. The Society’s editorial committee hopes that the content of its journals will be useful to your research, and also invites you to submit your own work to the journals.

Chairman of Committee
Hidehiko Nakagawa
Graduate School of Pharmaceutical Sciences, Nagoya City University
Read more
18,155 registered articles
(updated on August 01, 2025)
Online ISSN : 1347-5231
Print ISSN : 0031-6903
ISSN-L : 0031-6903
0.2
2024 Journal Impact Factor (JIF)
JOURNAL PEER REVIEWED FREE ACCESS FULL-TEXT HTML ADVANCE PUBLICATION
Scopus Pubmed
Featured article
Volume 145 (2025) Issue 7 Pages 629-637
Impact of Promotional Activities on Orexin Receptor Antagonists Prescription Rates and Usage of Sleep and Antipsychotic Medications: An Interrupted Time-series Analysis Study Read more
Editor's pick

This study demonstrated that targeted promotion of lemborexant, an orexin receptor antagonist, significantly increased its prescription rates. At the same time, it contributed to a notable decrease in the inappropriate use of non-benzodiazepine hypnotics and antipsychotics prescribed for delirium. While no change was observed in patient conditions, these findings suggest a meaningful shift toward safer and more appropriate pharmacological practices for sleep management. The study offers valuable insights for healthcare providers aiming to optimize medication use in clinical settings.

View all featured articles
Most viewed articles (June 2025)
Share this page
Browse by volume and issue
Announcements from publisher
feedback
Top